A new hypothesis of neurodegenerative diseases: The deleterious network hypothesis

Medical Hypotheses

Volumn 47, Issue 4, 1996, Pages 307-313

  Ying, W ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CALCIUM METABOLISM; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; NERVE CELL NETWORK; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0029806859     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90071-7     Document Type: Article

References (71)

1. Eisen A, Calne D B. Amyotrophic lateral sclerois, Parkinson's disease and Alzheimer's disease: phylogenetic disorders of the human neocortex sharing many characteristics. Can J Neurol Sci 1992; 19(Suppl): 117-120.
2. Bowling A C, Beal M F. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995; 56: 1149-1171
3. Eisen A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve 1995; 18: 741-752.
4. Semchuk K M, Love E J, Lee R G. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurol 1993; 43: 1173-1180.
5. Ying W. Deleterious network hypothesis of Alzheimer's disease. Med Hypotheses 1996; 46: 421-428.
6. Pellegrino-Giampeitro D E, Cherici G, Alestani M, Caria V, Moroni F. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci 1990; 10: 1035-1041.
7. Lafon-Cazal M, Pietrl S, Culcasi M, Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature 1995; 364: 535-537.
8. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies K J A. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 1990; 265: 16330-16336.
9. Bandy B, Davison A J. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging. J Free Radic Biol Med 1990; 8: 523-539.
10. Bowling A C, Schulz J B, Brown R H, Beal M F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61: 2322-2325.
11. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-812.
12. Ben-Shachar D, Youdim M B. Intranigral iron injection induces behavioral and biochemical 'Parkinsonism' in rats. J Neurochem 1991; 57: 2133-2135.
13. Przedborski S, Kostic V, Jackson-Lewis V et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992; 12: 1658-1667.
14. Dexter D T, Sian J, Rose S et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy Body disease. Ann Neurol 1994; 35: 38-44.
15. Ikebe S-I, Tanaka M, Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 1995; 28: 281-295.
16. Ince P G, Shaw P J, Candy J M et al. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci Lett 1994; 182: 87-90.
17. Shaw P J, Ince P G, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995; 38: 691-695.
18. Robberecht W, Sapp P, Viaene M K et al. Cu/Zn superoxide dismutase activity in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1994; 62: 384-387.
19. Uchino M, Ando Y, Tanka Y et al. Decrease in Cu/Zn- and Mn-superoxide dismutase activities in brain and spinal cord of patients with amyotrophic lateral sclerosis. J Neurol Sci 1994: 127: 61-67.
20. Rosen D R, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
21. Gurney M E, Pu H, Chiu A Y et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
22. Brown R H Jr. Amyotrophic lateral sclerosis: recent insights from genetic and transgenic mice. Cell 1995; 80: 687-692.
23. Dal Canto M C, Gurney M E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994; 145: 1271-1280.
24. Smith M A, Rudnicka-Nawrot M, Richey P L et al. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 1995; 64: 2660-2666.
25. Sexter D T, Carayon A, Javoy-Agid F et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953-1975.
26. Ferrante R J, MacKee A C, Kowall N W. Neurons sensitive to degeneration in Huntington's disease show evidence of oxidative membrane damage. Ann Neurol 1993; 34: 296.
27. May P C, Gray P N. The mechanisms of glutamate-induced degeneration of cultured Huntington's disease and control fibroblasts. J Neurol Sci 1985; 70: 101-112.
28. Beal M F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357-366.
29. Uhlhass S, Lange H. Striatal deficiency of L-pyroglutamic acid in Huntington's disease is accompanied by increased plasma levels. Brain Res 1988; 457: 196-199.
30. Horton T M, Graham B H, Corral-Debrinski M et al. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurol 1995; 45: 1879-1883.
31. Lohr J B. Oxygen radicals and neuropsychiatrie illness. Arch Gen Psychiatr 1991; 48: 1097-1106.
32. Iacopino A M, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 1990; 87: 4078-4082.
33. Perl D P, Gajdusek D C, Garruto R M. Yanagihara R T, Gibbs C J. Intraneuronal aluminum accumulation in amyotrophic sclerosis and Parkinsonism-dementia of Guam. Science 1982; 217: 1053-1055.
34. Vermersch P, Leys P, Pruvo J P, Clarisse J, Petit H. Parkinson's disease and basal ganglia calcifications: prevlence and clinico-radiological correlations. Clin Neurol Neurosurgery 1994; 94: 213-217.
35. Klockgether T, Turski L. Toward an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 1993; 34: 585-593.
36. Spencer P S, Nunn P B, Hugon J et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant toxin. Science 1987; 237: 517-522.
37. Olney J W, Zorumski C F, Stewart G R, Price M T, Wang G, Labruyere J. Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's diseases. Exp Neurol 1990; 108: 269-272.
38. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349: 414-418.
39. German D C, Mamaye K F, Sonsalla P K, Brooks B A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: sparing of calbindin-D28K containing cells Ann NY Acad Sci 1992; 648: 42-62.
40. 2+ regulation in aging neurons. Ann NY Acad Sci 1994; 747: 407-418.
41. Yasui M, Yase Y, Kihira T, Adachi K, Suzuki K. Magnesium and calcium contents in CNS tissues of anyotrophic lateral sclerosis patients from the Kii peninsula, Japan. Eur Neurol 1992; 32: 95-98.
42. Yoshimasu F, Yasui M, Yase Y et al. Studies on amyotrophic lateral sclerosis by neutron activation analysis. II. Comparative study of analytical results on Guam PD, Japanese ALS and Alzheimer disease. Folia Psychiatr et Neurol Jpn 1980; 34: 75-82.
43. Reiner A, Medina L, Figueredo-Cardenas G, Anfinson S. Brainstem motoneuron polls that are selectively resistant in amyotrophic lateral sclerosis are preferentially enriched in parvalbumin: evidence from monkey brainstem for a calcium-mediated mechanism in sporadic ALS. Exp Neurol 1995; 131: 239-250.
44. Yase Y. The basic process of amyotrophic lateral sclerosis as reflected in Kii peninsula and Guam. Proc 11th World Congr Neurol Amsterdam, Excerpta Medica 1977; 413-427.
45. Lanius R A, Paddon M B, Mezei M et al. A role for amplified protein kinase C activity in the pathogenesis of amyotrophic lateral sclerosis. J Neurochem 1995; 65: 927-930.
46. Bensimon G, Lacombiez L, Meininger V, the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-591.
47. Rothstein J D, Kammen M V, Levey A I, Martin L J, Kuncl R W. selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84.
48. Rothstein J D, Tsai G, Kuncl R W et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 20: 18-25.
49. Llinas R, Sugimori M, Cherksey B D et al. IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer. Proc Natl Acad Sci USA 1993; 90: 11743-11747.
50. Couratier P, Hugon J, Sindou P, Vallat J M, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993; 341: 265-268.
51. Perry T L, Hansen S. What excitotoxin kills striatal neurons in Huntington's disease: clues from neurochemical studies. Neurol 1990; 40: 20-24.
52. Watson D L, Carpenter C L, Marks S S, Greenberg D A. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease. Ann Neural 1988; 23: 303-305.
53. Beal M F, Kowell N W, Ellison D W, Mazurek M F, Swartz K J, Martin J B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168-171.
54. Ferrante R J, Kowall N W, Cipolloni P B, Storey E, Beal M F. Excitotoxin lesions in primates as a model of Huntington's disease: histopathologic and neurochemical characterization. Exp Neurol 1993; 119: 46-71.
55. Albin R L, Young A B, Penney J B et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990; 322: 1293-1298.
56. Lipton S A, Rosenberg P A. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl J Med 1994; 330: 613-621.
57. Ikebe S, Tanaka M, Ohno K et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 1990; 170: 1044-1048.
58. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994; 35: 204-210.
59. Hoyer S. Age-related changes in cerebral oxidative metabolism. Drugs Aging 1995; 6: 210-218.
60. Brouillet E, Hanraye P, Ferrante R J et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995; 92: 7105-7109.
61. Brown M D, Jun A S, Wallace D C. Maternal inherited Leber's hereditary optic neuropathy and dystonia associated with a mitochondrial DNA ND6 mutation at np 14459. Neurol 1994; 44: A285.
62. 99mTc]-d,1-HMPAO SPECT study. J Neurol Sci 1992; 107: 19-28.
63. Hirano A, Donnenfeld H, Sasaki S, Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1984; 43: 461-470.
64. Wong P C, Pardo C A, Borchelt D R et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-1116.
65. Mandler R N, Baca J M. Muscle lactate dehydrogenase activity is decreased in murine motor neuron disease. Brain Res 1992; 576: 337-338.
66. Collard J-F, Cote F, Jullen J-P. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995; 375 61-64.
67. Figlewicz D A, Krizus A, Martinoli M G et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic later sclerosis. Human Mol Genetics 1994; 3: 1757-1761.
68. Beal M F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119-130.
69. Alexianu M E, Ho B-K, Mohamed H, La Bella V, Smith B G, Appel S H. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994; 36: 846-858.
70. Olanow C W. A radical hypothesis for neurodegeneration. TINS 1993; 16: 439-443.
71. Mattson M P. Calcium as sculptor and destroyer of neural circuitry. Exp Gerontol 1992; 27: 29-49.